Beam Therapeutics (BEAM) News Today

Beam Therapeutics Inc. (NASDAQ:BEAM) shares are reacting to a fresh round of analyst revisions, with some firms lifting quarterly forecasts even as others trim multi-year outlooks and cut the price target. Shares have decreased following the more bearish guidance and target-price reduction, offset only in part by modest Q3 forecast upgrades.

• Positive Sentiment: William Blair raises its Q3 2025 EPS forecast to ($0.87) from ($0.93), and upgrades its FY2025 estimate to ($3.94) per share, citing operational improvements.
• Positive Sentiment: Leerink Partnrs marginally boosts its Q3 2025 EPS estimate to ($1.05) from ($1.06) and inches up both its FY2025 and FY2026 forecasts on expected stronger revenue trends.
• Neutral Sentiment: Analysts’ average recommendation remains a “Buy,” based on 14 covering brokerages, with the consensus price target largely unchanged. Beam Therapeutics Inc. Given Average Rating of "Buy" by Brokerages
• Negative Sentiment: Cantor Fitzgerald cuts its FY2025 EPS estimate sharply to ($4.42) from ($3.48), while projecting FY2026 EPS of ($4.10), close to the consensus loss of ($4.57) for 2025.
• Negative Sentiment: Wedbush lowers its Q3 2025 EPS forecast to ($1.11) from ($1.08) and trims guidance out through FY2029. Wedbush Decreases Earnings Estimates for Beam Therapeutics
• Negative Sentiment: Barclays cuts its price target to $21.00 from $25.00 and assigns an “Equal Weight” rating, citing valuation risks amid delayed clinical readouts. Barclays Lowers Beam Therapeutics Price Target to $21.00